TY - JOUR
T1 - Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer
T2 - Tumor SUV mean has superior prognostic value
AU - Higgins, Kristin A.
AU - Hoang, Jenny K.
AU - Roach, Michael C.
AU - Chino, Junzo
AU - Yoo, David S.
AU - Turkington, Timothy G.
AU - Brizel, David M.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Purpose: To evaluate the prognostic significance of different descriptive parameters in head-and-neck cancer patients undergoing pretreatment [F-18] fluoro-D-glucose-positron emission tomography (FDG-PET) imaging. Patients and Methods: Head-and-neck cancer patients who underwent FDG-PET before a course of curative intent radiotherapy were retrospectively analyzed. FDG-PET imaging parameters included maximum (SUV max), and mean (SUV mean) standard uptake values, and total lesion glycolysis (TLG). Tumors and lymph nodes were defined on co-registered axial computed tomography (CT) slices. SUV max and SUV mean were measured within these anatomic regions. The relationships between pretreatment SUV max, SUV mean, and TLG for the primary site and lymph nodes were assessed using a univariate analysis for disease-free survival (DFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Kaplan-Meier survival curves were generated and compared via the logrank method. SUV data were analyzed as continuous variables. Results: A total of 88 patients was assessed. Two-year OS, LRC, DMFS, and DFS for the entire cohort were 85%, 78%, 81%, and 70%, respectively. Median SUV max for the primary tumor and lymph nodes was 15.4 and 12.2, respectively. Median SUV mean for the primary tumor and lymph nodes was 7 and 5.2, respectively. Median TLG was 770. Increasing pretreatment SUV mean of the primary tumor was associated with decreased disease-free survival (p = 0.01). Neither SUV max in the primary tumor or lymph nodes nor TLG was prognostic for any of the clinical endpoints. Patients with pretreatment tumor SUV mean that exceeded the median value (7) of the cohort demonstrated inferior 2-year DFS relative to patients with SUV mean ≤ the median value of the cohort, 58% vs. 82%, respectively, p = 0.03. Conclusion: Increasing SUV mean in the primary tumor was associated with inferior DFS. Although not routinely reported, pretreatment SUV mean may be a useful prognostic FDG-PET parameter and should be further evaluated prospectively.
AB - Purpose: To evaluate the prognostic significance of different descriptive parameters in head-and-neck cancer patients undergoing pretreatment [F-18] fluoro-D-glucose-positron emission tomography (FDG-PET) imaging. Patients and Methods: Head-and-neck cancer patients who underwent FDG-PET before a course of curative intent radiotherapy were retrospectively analyzed. FDG-PET imaging parameters included maximum (SUV max), and mean (SUV mean) standard uptake values, and total lesion glycolysis (TLG). Tumors and lymph nodes were defined on co-registered axial computed tomography (CT) slices. SUV max and SUV mean were measured within these anatomic regions. The relationships between pretreatment SUV max, SUV mean, and TLG for the primary site and lymph nodes were assessed using a univariate analysis for disease-free survival (DFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Kaplan-Meier survival curves were generated and compared via the logrank method. SUV data were analyzed as continuous variables. Results: A total of 88 patients was assessed. Two-year OS, LRC, DMFS, and DFS for the entire cohort were 85%, 78%, 81%, and 70%, respectively. Median SUV max for the primary tumor and lymph nodes was 15.4 and 12.2, respectively. Median SUV mean for the primary tumor and lymph nodes was 7 and 5.2, respectively. Median TLG was 770. Increasing pretreatment SUV mean of the primary tumor was associated with decreased disease-free survival (p = 0.01). Neither SUV max in the primary tumor or lymph nodes nor TLG was prognostic for any of the clinical endpoints. Patients with pretreatment tumor SUV mean that exceeded the median value (7) of the cohort demonstrated inferior 2-year DFS relative to patients with SUV mean ≤ the median value of the cohort, 58% vs. 82%, respectively, p = 0.03. Conclusion: Increasing SUV mean in the primary tumor was associated with inferior DFS. Although not routinely reported, pretreatment SUV mean may be a useful prognostic FDG-PET parameter and should be further evaluated prospectively.
KW - FDG-PET
KW - Head and neck cancer
KW - SUV
UR - http://www.scopus.com/inward/record.url?scp=84855850707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855850707&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2010.11.050
DO - 10.1016/j.ijrobp.2010.11.050
M3 - Article
C2 - 21277108
AN - SCOPUS:84855850707
SN - 0360-3016
VL - 82
SP - 548
EP - 553
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -